| Specialties | Accepting New Patients |
|---|---|
|
Oncology
Board Certified in 1995 |
|
| Hematology/Oncology |
|
Gender: F
Years in practice: 20
Main Line HealthCare Physician
Medical School:
Medical College of Pennsylvania
Residency:
Chandler Medical Center, University of Kentucky
Fellowship:
Fox Chase Cancer Center
Affiliations:
Clinical/Dept Titles:
Attending Physician
MLHC Hem/Onc Assoc. (view other physicians at this practice)
Office Information
|
Paoli Hospital Cancer Center
255 West Lancaster Avenue
Paoli, PA 19301TEL: 484.565.1600 FAX: 610.647.2006 View Map | Get Directions |
Access Information:
|
| Hours: | Weekdays |
| Hours: | Weekdays |
Access Information:
Handicap Access
Hours:Weekdays
MLHC Hem/Onc Assoc.
Access Information:
Handicap Access
Hours:Weekdays
MLHC Hem/Onc Assoc. Exton, PA 19341
Access Information:
Public Transportation,
Handicap Access
Hours:Weekdays
To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.
Susan Zuk,
RN - Program Manager
Phone: 484-565-1608
Margaret Cook,
Office Manager
Phone: 484-565-1413
Recent Clinical Studies Published
PUBLICATIONS
Lewis, NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ. Phase I and Pharmacokinetic Study of Irinotecan in Combination with Raltitrexed. Cancer Chemother. Pharmacol. 50:257-265, 2002.
Szarka CE, Hamilton TC, Klein-Szanto AJP, and Ozols RF. Chemoprevention of Ovarian Cancer. Ovarian Cancer, Oxford University Press, New York, NY pp. 153-160, 2002.
Szarka CE, Yao K-S, Pfeiffer GR, Balshem AM, Litwin S, Frucht H, Goosenberg E, Engstrom P, Clapper ML, and O’Dwyer PJ. Chronic Dosing of Oltipraz in People at Increased Risk for Colorectal Cancer. Cancer Detect. Prev. 25(4):352-361, 2001.
Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL, Trimodality Therapy for Advanced Gallbladder Cancer. Am. Surg. 67:277-284, 2001.
Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halbherr T, Qian M., and Gallo JM. Phase I Pharmacokinetic Trial of Perillyl Alcohol (NCS 641066) in Patients with Refractory Solid Malignancies Clin Cancer Res 6:3071-3080, 2000.
O’Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM. Pharmacokinetics of the Chemopreventive Agent Oltipraz and of its Metabolite M3 in Human Subjects After a Single Oral Dose. Clinical Cancer Research 6(12):4692-4696, 2000.
Diefenbach MA, Szarka CE, Knowles JC, Clapper M, Miller SM, and Engstrom PE. Psychological Factors Associated with Participation and Retention in Lung Cancer Chemoprevention Trial. Cancer Detect. Prev.(under revision), 2000.
Szarka CE, Ehya H, Klein-Szanto A, Clapper M, Unger M, King E, Cecelia M, Andrew B, Gallo JM, Litwin S, Engstrom PF, Berg C. A Phase II Trial of Oltipraz as a Chemopreventive Agent for Lung Dysplasia. Proc. Am. Soc. Clin. Oncol. 19:1946, 2000.
Hudes G, Schol J, Baab J, Rogatko A, Bol C, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ, Weiner L. Phase I Clinical and Pharmacokinetic Trial of the Farnesyltransferase Inhibitor R115777 on a 21-day Dosing Schedule. Proc. Am.Soc. Clin. Oncol. 18:601, 1999.
Recent Honors, Awards, Citations
Personal Quote
Statement of Practice Philosophy:
To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.
Current Memberships and Activities
American Society of Clinical OncologyAmerican Association for Cancer ResearchAmerican College of PhysiciansPennsylvania Medical Society
| Specialties: | Oncology
(Board Certified in
1995)
-
Accepting New Patients
Hematology/Oncology - Accepting New Patients |
|---|
Gender: F
Years in practice: 20
Main Line HealthCare Physician
Medical School:
Medical College of Pennsylvania
Residency:
Chandler Medical Center, University of Kentucky
Fellowship:
Fox Chase Cancer Center
Affiliations:
Clinical/Dept Titles:
Attending Physician
Practice Name:
MLHC Hem/Onc Assoc.
Locations:
| Paoli Hospital Cancer Center
255 West Lancaster Avenue
Paoli, PA 19301TEL: 484.565.1600 FAX: 610.647.2006 |
|
| Main Line Health Center
599 Arcola Road
Collegeville, PA 19426TEL: 484.565.1600 FAX: 610.647.2006 |
|
| 495 Thomas Jones Way, Suite 300
Exton, PA 19341TEL: 484.565.1600 FAX: 610.647.2006 |
|
To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.
Susan Zuk,
RN - Program Manager
Phone: 484-565-1608
Margaret Cook,
Office Manager
Phone: 484-565-1413
Recent Clinical Studies Published
PUBLICATIONS
Lewis, NL, Scher R, Gallo JM, Engstrom PF, Szarka CE, Litwin S, Adams AL, Kilpatrick D, Brady D, Weiner LM, Meropol NJ. Phase I and Pharmacokinetic Study of Irinotecan in Combination with Raltitrexed. Cancer Chemother. Pharmacol. 50:257-265, 2002.
Szarka CE, Hamilton TC, Klein-Szanto AJP, and Ozols RF. Chemoprevention of Ovarian Cancer. Ovarian Cancer, Oxford University Press, New York, NY pp. 153-160, 2002.
Szarka CE, Yao K-S, Pfeiffer GR, Balshem AM, Litwin S, Frucht H, Goosenberg E, Engstrom P, Clapper ML, and O’Dwyer PJ. Chronic Dosing of Oltipraz in People at Increased Risk for Colorectal Cancer. Cancer Detect. Prev. 25(4):352-361, 2001.
Sasson AR, Hoffman JP, Ross E, Meropol NJ, Szarka CE, Freedman G, Pinover W, Pingpank JF, Eisenberg BL, Trimodality Therapy for Advanced Gallbladder Cancer. Am. Surg. 67:277-284, 2001.
Hudes GR, Szarka CE, Adams A, Ranganathan S, McCauley RA, Weiner LM, Langer CJ, Litwin S, Yeslow G, Halbherr T, Qian M., and Gallo JM. Phase I Pharmacokinetic Trial of Perillyl Alcohol (NCS 641066) in Patients with Refractory Solid Malignancies Clin Cancer Res 6:3071-3080, 2000.
O’Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM. Pharmacokinetics of the Chemopreventive Agent Oltipraz and of its Metabolite M3 in Human Subjects After a Single Oral Dose. Clinical Cancer Research 6(12):4692-4696, 2000.
Diefenbach MA, Szarka CE, Knowles JC, Clapper M, Miller SM, and Engstrom PE. Psychological Factors Associated with Participation and Retention in Lung Cancer Chemoprevention Trial. Cancer Detect. Prev.(under revision), 2000.
Szarka CE, Ehya H, Klein-Szanto A, Clapper M, Unger M, King E, Cecelia M, Andrew B, Gallo JM, Litwin S, Engstrom PF, Berg C. A Phase II Trial of Oltipraz as a Chemopreventive Agent for Lung Dysplasia. Proc. Am. Soc. Clin. Oncol. 19:1946, 2000.
Hudes G, Schol J, Baab J, Rogatko A, Bol C, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ, Weiner L. Phase I Clinical and Pharmacokinetic Trial of the Farnesyltransferase Inhibitor R115777 on a 21-day Dosing Schedule. Proc. Am.Soc. Clin. Oncol. 18:601, 1999.
Recent Honors, Awards, Citations
Personal Quote
Statement of Practice Philosophy:
To provide the highest quality treatment possible in a supportive, caring environment, utilizing the most effective and innovative therapies, while focused on each individual's special needs and goals of care.
Current Memberships and Activities
American Society of Clinical OncologyAmerican Association for Cancer ResearchAmerican College of PhysiciansPennsylvania Medical Society
Membership on the medical staff of any of our hospitals does not constitute an employment or agency relationship.
Membership on the medical staff of any of our hospitals does not constitute an employment or agency relationship.
New Appointments
1.866.CALL.MLH
© 2013 Main Line Health